These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

94 related articles for article (PubMed ID: 9583607)

  • 1. The AIDS incubation period in the UK estimated from a national register of HIV seroconverters. UK Register of HIV Seroconverters Steering Committee.
    AIDS; 1998 Apr; 12(6):659-67. PubMed ID: 9583607
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The UK register of HIV seroconverters: methods and analytical issues. UK register of HIV seroconverters (UKRHS) Steering Committee.
    Epidemiol Infect; 1996 Oct; 117(2):305-12. PubMed ID: 8870628
    [TBL] [Abstract][Full Text] [Related]  

  • 3. How soon after HIV seroconversion is antiretroviral therapy initiated? The UK Register of HIV Seroconverters Steering Committee.
    AIDS; 1999 Jul; 13(10):1241-7. PubMed ID: 10416529
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The practical significance of potential biases in estimates of the AIDS incubation period distribution in the UK register of HIV seroconverters.
    Porter K; Johnson AM; Phillips AN; Darbyshire JH
    AIDS; 1999 Oct; 13(14):1943-51. PubMed ID: 10513654
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Importance of age at infection with HIV-1 for survival and development of AIDS in UK haemophilia population. UK Haemophilia Centre Directors' Organisation.
    Darby SC; Ewart DW; Giangrande PL; Spooner RJ; Rizza CR
    Lancet; 1996 Jun; 347(9015):1573-9. PubMed ID: 8667864
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Survival, progression to AIDS and immunosuppression in HIV-positive individuals before and after the introduction of the highly active antiretroviral therapy (HAART)].
    Pezzotti P; Dorrucci M; Donisi A; Cusini M; Mazzarello G; De Luca A; Salassa B; Ursitti MA; Giuliani M; Rezza G;
    Epidemiol Prev; 2003; 27(6):348-55. PubMed ID: 15058363
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Time from HIV-1 seroconversion to AIDS and death before widespread use of highly-active antiretroviral therapy: a collaborative re-analysis. Collaborative Group on AIDS Incubation and HIV Survival including the CASCADE EU Concerted Action. Concerted Action on SeroConversion to AIDS and Death in Europe.
    Lancet; 2000 Apr; 355(9210):1131-7. PubMed ID: 10791375
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Antiretroviral treatment and progression to AIDS in HIV seroconverters from different risk groups. HIV Italian Seroconversion Study.
    Dorrucci M; Pezzotti P; Phillips AN; Alliegro MB; Rezza G
    AIDS; 1997 Mar; 11(4):461-7. PubMed ID: 9084793
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Progression of HIV: follow-up of Edinburgh injecting drug users with narrow seroconversion intervals in 1983-1985.
    Brettle RP; McNeil AJ; Burns S; Gore SM; Bird AG; Yap PL; MacCallum L; Leen CS; Richardson AM
    AIDS; 1996 Apr; 10(4):419-30. PubMed ID: 8728047
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effectiveness of potent antiretroviral therapy on time to AIDS and death in men with known HIV infection duration. Multicenter AIDS Cohort Study Investigators.
    Detels R; Muñoz A; McFarlane G; Kingsley LA; Margolick JB; Giorgi J; Schrager LK; Phair JP
    JAMA; 1998 Nov; 280(17):1497-503. PubMed ID: 9809730
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The incubation period to AIDS in injecting drug users estimated from prevalent cohort data, accounting for death prior to an AIDS diagnosis.
    Hendriks JC; Satten GA; van Ameijden EJ; van Druten HA; Coutinho RA; van Griensven GJ
    AIDS; 1998 Aug; 12(12):1537-44. PubMed ID: 9727576
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Factors associated with progression to AIDS and mortality in a cohort of HIV-infected patients with hemophilia followed up since seroconversion.
    Santagostino E; Gringeri A; Cultraro D; Tradati F; Siracusano L; Marinoni A; Mannucci PM
    Cell Mol Biol (Noisy-le-grand); 1995 May; 41(3):371-80. PubMed ID: 7580830
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Long-term perspective on the prevalent-cohort biases in studies of human immunodeficiency virus progression.
    Alcabes P; Pezzotti P; Phillips AN; Rezza G; Vlahov D
    Am J Epidemiol; 1997 Oct; 146(7):543-51. PubMed ID: 9326431
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Gender differences in progression to AIDS and death from HIV seroconversion in a cohort of injecting drug users from 1986 to 2001.
    García de la Hera M; Ferreros I; del Amo J; García de Olalla P; Pérez Hoyos S; Muga R; del Romero J; Guerrero R; Hernández-Aguado I;
    J Epidemiol Community Health; 2004 Nov; 58(11):944-50. PubMed ID: 15483312
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Clinical characteristics and prognostic value of acute retroviral syndrome among injecting drug users. Italian Seroconversion Study.
    Dorrucci M; Rezza G; Vlahov D; Pezzotti P; Sinicco A; Nicolosi A; Lazzarin A; Galai N; Gafà S; Pristerà R
    AIDS; 1995 Jun; 9(6):597-604. PubMed ID: 7662199
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Changes in the uptake of antiretroviral therapy and survival in people with known duration of HIV infection in Europe: results from CASCADE.
    CASCADE (Concerted Action on SeroConversion to AIDS and Death in Europe) Collaboration
    HIV Med; 2000 Oct; 1(4):224-31. PubMed ID: 11737353
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Survival of HIV-infected treatment-naive individuals with documented dates of seroconversion in Rakai, Uganda.
    Lutalo T; Gray RH; Wawer M; Sewankambo N; Serwadda D; Laeyendecker O; Kiwanuka N; Nalugoda F; Kigozi G; Ndyanabo A; Bwanika JB; Reynolds SJ; Quinn T; Opendi P
    AIDS; 2007 Nov; 21 Suppl 6():S15-9. PubMed ID: 18032934
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Survival following HIV infection of a cohort followed up from seroconversion in the UK.
    Ewings FM; Bhaskaran K; McLean K; Hawkins D; Fisher M; Fidler S; Gilson R; Nock D; Brettle R; Johnson M; Phillips A; Porter K;
    AIDS; 2008 Jan; 22(1):89-95. PubMed ID: 18090396
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Determinants of progression to AIDS in HIV-infected individuals: an update from the Italian Seroconversion Study.
    Rezza G
    J Acquir Immune Defic Syndr Hum Retrovirol; 1998; 17 Suppl 1():S13-6. PubMed ID: 9586645
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effect of highly active antiretroviral therapy on multiple AIDS-defining illnesses among male HIV seroconverters.
    Cain LE; Cole SR; Chmiel JS; Margolick JB; Rinaldo CR; Detels R
    Am J Epidemiol; 2006 Feb; 163(4):310-5. PubMed ID: 16371516
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.